Biogen (BIIB) stock gains as the company posts mid-stage trial data for an Alzheimer's therapy developed with Ionis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results